Immatics NV (IMTX)

[FACT-MASTER]

I'm not 100% sure, however wouldn't this be an 80% ORR ( objective response rate) 20/25 patients?

"55% (11/20) of efficacy-evaluable pts treated in the escalation phase, including initial low MABEL-based starting DLs, achieved disease control (SD/PR). Among these were pts with ovarian cancer, sqNSCLC, gastric cancer, HNSCC, melanoma, and neuroendocrine carcinoma. 45% (9/20) of the pts showed shrinkage of target lesions (median -21.7%), including 3 pts with durable confirmed PRs at 4+, 10+ and 11+ months after first infusion."

https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/232#presentation-abstract-895832222418